IR Insights: Recapping Our Third Quarter 2025 Earnings Report
Earlier today, Moderna reported financial results and provided business updates for the third quarter of 2025.
Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel, President Stephen Hoge, and CFO Jamey Mock.
Forward-Looking Statements
This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's 2025 financial framework, including its expected revenue range, operating expenses and year-end cash balance; demand for Moderna’s products and Moderna’s ability to drive future sales growth; Moderna's continued cost discipline and its ability to deliver cost efficiencies across the business; Moderna’s anticipated cash breakeven in 2028; anticipated regulatory filings and potential approvals; vaccination rates and the size of the COVID vaccine market; anticipated geographic expansion; and anticipated milestones for Moderna's pipeline programs, including potential near-term catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.